News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
Thursday, January 16, 2025InflaRx announced that the European Commission EC has granted marketing authorization under exceptional circumstances for GOHIBIC vilobelimab for the treatment of adult patients with SARSCoVinduced acute respiratory distress syndrome ARDS who are rec...
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Wednesday, January 15, 2025Artelo Biosciences Inc a clinicalstage pharmaceutical company focused on modulating lipidsignaling pathways to develop treatments for people living with cancer pain or dermatologic and neurological conditions today announced the completed safety revi...
Firefly Neuroscience Discovers Breakthrough Cognitive Brain Age Biomarker Using its FDA-Cleared BNA™ Platform
Wednesday, January 15, 2025Firefly Neuroscience Inc an Artificial Intelligence AI company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders today announced the advancement of research to assess a patients bra...
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
Monday, January 13, 2025Inozyme Pharma Inc a clinicalstage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function today announced positive interim data from its ENERGY trial and Expanded Access Progr...
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
Friday, January 10, 2025Climb Bio Inc announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co Ltd for rights to develop and commercialize MIL now CLYM an antiAPRIL A PRoliferationInducing Ligand monoclonal antibody in the territory outs...
Ori Biotech Expands Team to Advance IRO Commercialization and Industry Partnerships
Friday, January 10, 2025Oribiotech Ltd Ori a leader in cell and gene therapy CGT manufacturing technology today announces new additions to its leadership including the appointment of two new members to its senior team and new members to its Strategic Advisory Board SAB This...
NurExone Biologic Secures Master Cell Bank
Thursday, January 09, 2025NurExone Biologic Inc a developer of exosomebased therapies for regenerative medicine is pleased to announce that it has acquired a master cell bank from a US manufacturer for an undisclosed amount the Acquisition The Acquisition marks a major step i...
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
Thursday, January 09, 2025Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease the most common form of inherited macular degeneration This groundbreaking study published in Nature Medicine on January demonstrates...
Helix Enters Multi-Year Strategic Collaboration with GSK to Support Precision Medicine Research
Wednesday, January 08, 2025Helix has entered into a multiyear strategic collaboration with GSK to support the development of precision medicine Under the agreement GSK will gain access to Helixs expanding GenoSphere cohorts
RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
Wednesday, January 08, 2025RESTEM a clinicalstage biotechnology company that develops offtheshelf nextgeneration cell therapies designed to modulate the immune system today announced that the US Food and Drug Administration FDA has granted Fast Track designation for RestemL t...
